Legal status by country
Is Degarelix legal?
Written by Aaron CuhaReviewed Sep 2026
How Degarelix is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Approved | Approved | Approved | Approved |
| Classification | FDA-approved, prescription only | Licensed, prescription only (MHRA) | TGA-registered, prescription only | Health Canada approved, prescription only |
| Note | NDA 022201, approved 24 December 2008, Ferring, marketed as Firmagon. The indication is advanced prostate cancer and nothing else. Subcutaneous injection only. | Licensed as Firmagon for advanced hormone-dependent prostate cancer. Prescription only, specialist initiated. | Registered for advanced hormone-dependent prostate cancer. Prescription only. | Approved for advanced hormone-dependent prostate cancer. Prescription only. |
US FDA status: FDA-approved on 24 December 2008 under NDA 022201, marketed as Firmagon, for treatment of patients with advanced prostate cancer. No boxed warning. Not approved for localised prostate cancer management outside that indication, for any use in women, or for any use in healthy adults.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.